Cargando…

Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer

Selective induction of breast cancer apoptosis is viewed as the mainstay of various ongoing oncology drug discovery programs. Passerini scaffolds have been recently exploited as selective apoptosis inducers via a caspase 3/7 dependent pathway. Herein, the optimized Passerini caspase activators were...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoup, Mohammed Salah, Wahby, Yasmin, Abdel-Hamid, Hamida, Abu-Serie, Marwa M., Ramadan, Sherif, Barakat, Assem, Teleb, Mohamed, Ismail, Magda M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509784/
https://www.ncbi.nlm.nih.gov/pubmed/37736568
http://dx.doi.org/10.1039/d3ra04029a
_version_ 1785107828674920448
author Ayoup, Mohammed Salah
Wahby, Yasmin
Abdel-Hamid, Hamida
Abu-Serie, Marwa M.
Ramadan, Sherif
Barakat, Assem
Teleb, Mohamed
Ismail, Magda M. F.
author_facet Ayoup, Mohammed Salah
Wahby, Yasmin
Abdel-Hamid, Hamida
Abu-Serie, Marwa M.
Ramadan, Sherif
Barakat, Assem
Teleb, Mohamed
Ismail, Magda M. F.
author_sort Ayoup, Mohammed Salah
collection PubMed
description Selective induction of breast cancer apoptosis is viewed as the mainstay of various ongoing oncology drug discovery programs. Passerini scaffolds have been recently exploited as selective apoptosis inducers via a caspase 3/7 dependent pathway. Herein, the optimized Passerini caspase activators were manipulated to synergistically induce P53-dependent apoptosis via modulating the closely related P53-MDM2 signaling axis. The adopted design rationale and synthetic routes relied on mimicking the general thematic features of lead MDM2 inhibitors incorporating multiple aromatic rings. Accordingly, the cyclization of representative Passerini derivatives and related Ugi compounds into the corresponding diphenylimidazolidine and spiro derivative was performed, resembling the nutlin-based and spiro MDM-2 inhibitors, respectively. The study was also extended to explore the apoptotic induction capacity of the scaffold after simplification and modifications. MTT assay on MCF-7 and MDA-MB231 breast cancer cells compared to normal fibroblasts (WI-38) revealed their promising cytotoxic activities. The flexible Ugi derivatives 3 and 4, cyclic analog 8, Passerini adduct 12, and the thiosemicarbazide derivative 17 were identified as the study hits regarding cytotoxic potency and selectivity, being over 10-folds more potent (IC(50) = 0.065–0.096 μM) and safer (SI = 4.4–18.7) than doxorubicin (IC(50) = 0.478 μM, SI = 0.569) on MCF-7 cells. They promoted apoptosis induction via caspase 3/7 activation (3.1–4.1 folds) and P53 induction (up to 4 folds). Further apoptosis studies revealed that these compounds enhanced gene expression of BAX by 2 folds and suppressed Bcl-2 expression by 4.29–7.75 folds in the treated MCF-7 cells. Docking simulations displayed their plausible binding modes with the molecular targets and highlighted their structural determinants of activities for further optimization studies. Finally, in silico prediction of the entire library was computationally performed, showing that most of them could be envisioned as drug-like candidates.
format Online
Article
Text
id pubmed-10509784
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-105097842023-09-21 Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer Ayoup, Mohammed Salah Wahby, Yasmin Abdel-Hamid, Hamida Abu-Serie, Marwa M. Ramadan, Sherif Barakat, Assem Teleb, Mohamed Ismail, Magda M. F. RSC Adv Chemistry Selective induction of breast cancer apoptosis is viewed as the mainstay of various ongoing oncology drug discovery programs. Passerini scaffolds have been recently exploited as selective apoptosis inducers via a caspase 3/7 dependent pathway. Herein, the optimized Passerini caspase activators were manipulated to synergistically induce P53-dependent apoptosis via modulating the closely related P53-MDM2 signaling axis. The adopted design rationale and synthetic routes relied on mimicking the general thematic features of lead MDM2 inhibitors incorporating multiple aromatic rings. Accordingly, the cyclization of representative Passerini derivatives and related Ugi compounds into the corresponding diphenylimidazolidine and spiro derivative was performed, resembling the nutlin-based and spiro MDM-2 inhibitors, respectively. The study was also extended to explore the apoptotic induction capacity of the scaffold after simplification and modifications. MTT assay on MCF-7 and MDA-MB231 breast cancer cells compared to normal fibroblasts (WI-38) revealed their promising cytotoxic activities. The flexible Ugi derivatives 3 and 4, cyclic analog 8, Passerini adduct 12, and the thiosemicarbazide derivative 17 were identified as the study hits regarding cytotoxic potency and selectivity, being over 10-folds more potent (IC(50) = 0.065–0.096 μM) and safer (SI = 4.4–18.7) than doxorubicin (IC(50) = 0.478 μM, SI = 0.569) on MCF-7 cells. They promoted apoptosis induction via caspase 3/7 activation (3.1–4.1 folds) and P53 induction (up to 4 folds). Further apoptosis studies revealed that these compounds enhanced gene expression of BAX by 2 folds and suppressed Bcl-2 expression by 4.29–7.75 folds in the treated MCF-7 cells. Docking simulations displayed their plausible binding modes with the molecular targets and highlighted their structural determinants of activities for further optimization studies. Finally, in silico prediction of the entire library was computationally performed, showing that most of them could be envisioned as drug-like candidates. The Royal Society of Chemistry 2023-09-20 /pmc/articles/PMC10509784/ /pubmed/37736568 http://dx.doi.org/10.1039/d3ra04029a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Ayoup, Mohammed Salah
Wahby, Yasmin
Abdel-Hamid, Hamida
Abu-Serie, Marwa M.
Ramadan, Sherif
Barakat, Assem
Teleb, Mohamed
Ismail, Magda M. F.
Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer
title Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer
title_full Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer
title_fullStr Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer
title_full_unstemmed Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer
title_short Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer
title_sort reinvestigation of passerini and ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and p53-mdm2 signaling for halting breast cancer
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509784/
https://www.ncbi.nlm.nih.gov/pubmed/37736568
http://dx.doi.org/10.1039/d3ra04029a
work_keys_str_mv AT ayoupmohammedsalah reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT wahbyyasmin reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT abdelhamidhamida reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT abuseriemarwam reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT ramadansherif reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT barakatassem reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT telebmohamed reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer
AT ismailmagdamf reinvestigationofpasseriniandugiscaffoldsasmultistepapoptoticinducersviadualmodulationofcaspase37andp53mdm2signalingforhaltingbreastcancer